Substituted dihydronaphthalenes as efflux pump inhibitors of Staphylococcus aureus

Niranjan Thota, Mallepally V. Reddy, Ashwani Kumar, Inshad A. Khan, Payare L. Sangwan, Nitin P. Kalia, Jawahir L. Koul, Surrinder Koul

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


A new series of 3-(substituted-3,4-dihydronaphthyl)-2-propenoic acid amides has been prepared through convergent synthetic strategies and tested in combination with ciprofloxacin against NorA overexpressing Staphylococcus aureus 1199B as test strain for potentiating of the drug activity. Out of 24 compounds evaluated, 12 compounds potentiated the activity of ciprofloxacin and resulted in 2-16 fold reduction in the MIC (4-0.5 μg/mL) of the drug. The failure of these efflux pump inhibitors (EPIs) to potentiate the activity of ciprofloxacin when tested against NorA knock out S. aureus SA-K1758 established their identity as NorA inhibitors. The structure of all these newly synthesised compounds was confirmed by spectral data. The present communication describes the synthesis, bioevaluation, structure activity relationship and mechanism of action of these EPIs. Design and synthesis of new series of 3-(substituted 3,4-dihydronaphthyl)- propenoic acid amides as efflux pump inhibitors has resulted in the MIC reduction of ciprofloxacin.

Original languageEnglish
Pages (from-to)3607-3616
Number of pages10
JournalEuropean Journal of Medicinal Chemistry
Issue number9
StatePublished - Sep 2010
Externally publishedYes


  • Bacterial NorA efflux pump inhibitors
  • Ciprofloxacin
  • Ethidium bromide
  • Eugenol
  • Staphylococcus aureus
  • Tetralone


Dive into the research topics of 'Substituted dihydronaphthalenes as efflux pump inhibitors of Staphylococcus aureus'. Together they form a unique fingerprint.

Cite this